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Maternal Administration of Solithromycin, a New, Potent, Broad-
Spectrum Fluoroketolide Antibiotic, Achieves Fetal and Intra-Amniotic
Antimicrobial Protection in a Pregnant Sheep Model
Jeffrey A. Keelan,a Matthew W. Kemp,a Matthew S. Payne,a David Johnson,b Sarah J. Stock,c Masatoshi Saito,d
Prabhavathi Fernandes,e John P. Newnhama
‹School of Women’s and Infants’ Health, The University of Western Australia, Perth, Western Australia, Australiaa; MicroConstants Inc., San Diego, California, USAb;
Department of Obstetrics & Gynecology, University of Edinburgh, Edinburgh, United Kingdomc; Division of Perinatal Medicine, Tohoku University Hospital, Sendai, Japand;
Cempra, Inc., Chapel Hill, North Carolina, USAe
Solithromycin (CEM-101) is a new antibiotic that is highly potent againstUreaplasma andMycoplasma spp. and active against
many other antibiotic-resistant organisms.We have explored the maternal-amniotic-fetal pharmacokinetics of CEM-101 in a
pregnant sheep model to assess its potential for treating intrauterine and antenatal infection. Chronically catheterized pregnant
ewes (n 6 or 7) received either a single maternal intravenous (i.v.) infusion of CEM-101 (10 mg/kg of body weight), a single
intra-amniotic (i.a.) injection (1.4 mg/kg of estimated fetal weight), or a combined i.v. and i.a. dose. Maternal plasma (MP), fetal
plasma (FP), and amniotic fluid (AF) samples were taken via catheter at intervals of 0 to 72 h postadministration, and concentra-
tions of solithromycin and its bioactive polar metabolites (N-acetyl [NAc]–CEM-101 and CEM-214) were determined. Following
maternal i.v. infusion, peak CEM-101 concentrations inMP, FP, and AF were 1,073, 353, and 214 ng/ml, respectively, represent-
ing a maternal-to-fetal plasma transfer efficiency of 34%. A single maternal dose resulted in effective concentrations (>30 ng/ml)
inMP, FP, and AF sustained for>12 h. NAc–CEM-101 and CEM-214 exhibited delayed accumulation and clearance in FP and
AF, resulting in an additive antimicrobial effect (>48 h). Intra-amniotic solithromycin injection resulted in elevated (50g/
ml) and sustained CEM-101 concentrations in AF and significant levels in FP, although the efficiency of amniotic-to-fetal trans-
fer was low (1.5%). Combined i.v. and i.a. administration resulted in primarily additive concentrations of CEM-101 in all three
compartments. Our findings suggest that CEM-101 may provide, for the first time, an effective antimicrobial approach for the
prevention and treatment of intrauterine infection and early prevention of preterm birth.
Intrauterine infection and inflammation play a well-recog-nized role in the etiology of spontaneous preterm labor and
birth, particularly in deliveries less than 32 weeks of gestation
or those complicated by preterm prelabor rupture of mem-
branes (PPROM) (1, 2). The origin of the infection is typically
the vaginal flora: microorganisms are hypothesized to breach
the cervical barrier, infect the fetal membranes, and eventually
colonize the amniotic cavity (2–4). The vigorous inflammatory
response that ensues is responsible for activation of myome-
trial contractions, membrane degradation, and rupture and
cervical ripening, leading to labor and delivery (2, 5, 6). Intra-
cellular organisms of the Mollicutes class, namely, Ureaplasma
andMycoplasma species, are themicroorganismsmost commonly
isolated from the amniotic fluid (AF) of preterm deliveries (7, 8)
and have been shown to be capable of eliciting preterm labor via a
robust intrauterine inflammatory response in a dose-dependent
fashion (9–11). Numerous other bacterial classes have also been
identified in infected amniotic fluid samples, including strepto-
cocci, staphylococci, enterococci, Fusobacterium spp., Bacteroides
spp., and Haemophilus spp. (8, 12).
A variety of clinical trials ofmaternal antibiotic administration
have been performed to attempt to prevent or treat intrauterine
infection with the aim of reducing the rates of preterm birth and
associated neonatal morbidities; however, the benefits of these
interventions have been unconvincing (13). The conclusions
reached by the authors of several recent meta-analyses are that
there is no evidence that treatment of women at risk of infection-
driven preterm birth with antibiotics prophylactically or upon
presentation with preterm labor reduces the rates of preterm de-
livery or improves neonatal outcomes (14–16). Not all researchers
are in agreement, however. In some studies in which antibiotics
(primarily clindamycin) have been administered to high-risk
women prior to 22 weeks of gestation, significant reductions in
rates of delivery before 37 and 33 weeks and in late miscarriage
have been documented (17).
The reasons for the generally disappointing results of antibiotic
interventions are likely severalfold, but the choice of antibiotic is a
key factor. Macrolide antibiotics such as erythromycin and azi-
thromycin are widely prescribed during pregnancy for the treat-
ment of a variety of microbial infections, as they are perceived to
be well tolerated, effective in treating important microorganisms
such asUreaplasma andMycoplasma spp., and free of serious ma-
ternal and fetal side effects (18–21). Erythromycin is the most
frequently administered antibiotic for treatment of PPROMbased
on the findings of the ORACLE I trial (22). However, there is
strong evidence that systemic maternal erythromycin administra-
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tion is largely ineffective in eradicating intrauterine Ureaplasma
species infection (23). In an experimental sheep model of intra-
uterine Ureaplasma species colonization during pregnancy, we
have shown that maternal intramuscular (i.m.) erythromycin ad-
ministration does not eradicate Ureaplasma species infection
from the amniotic fluid, chorioamnion, umbilical cord, or fetal
lung (24). This is likely attributable to poor transplacental/trans-
amniotic passage of macrolides. In the ex vivo perfused human
placenta model, the transfer rate of macrolides is only 2 to 4%
(25).
We recently showed that in sheep, maternal macrolide admin-
istration fails to deliver effective chemotherapeutic levels to either
the fetal circulation or the amniotic cavity (26). In vivo studies
confirm that the degree of erythromycin passage to the human
fetus is low and variable (27, 28), while the extent of maternal-to-
amniotic fluid transfer is more uncertain. A recent study in preg-
nant women at term reported that the transfer of azithromycin
from maternal circulation to AF was more efficient than the ma-
ternal-to-fetal plasma transfer, although resulting AF concentra-
tions (150 ng/ml) still failed to reach the MIC90 forUreaplasma
spp. (500 ng/ml) (29). Interestingly, a recent study in pregnant
primates with intra-amniotic (i.a.) Ureaplasma infection showed
that a sustained 10-day maternal course of azithromycin (12.5
mg/kg of body weight) achieved effective antimicrobial levels in
the amniotic fluid and low levels in the fetal circulation (30); how-
ever, although the infection was cleared in 90% of animals, intra-
amniotic and fetal inflammation remained evident following
azithromycin treatment, and pregnancy length was extended by
only 7 to 10 days, with all animals delivering preterm (30). From
these studies, it is clear that intrauterine infections are difficult
to eradicate and a more potent antibiotic with better maternal-
amniotic-fetal transfer properties is required to eliminate both
fetal and amniotic infection, in combination with an effective
anti-inflammatory therapeutic to prevent the adverse conse-
quences of inflammation within the amniotic cavity.
Solithromycin (CEM-101) is a novel macrolide/fluoroketolide
antibiotic which exhibits broad-spectrum activity against Gram-
positive and some Gram-negative organisms, including Neisseria
gonorrhoeae, Chlamydia trachomatis, Haemophilus spp., strepto-
cocci, and enterococci (31–37). It is exceptionally potent against
Ureaplasma parvum, Ureaplasma urealyticum, and Mycoplasma
hominis (125 to 250 times more potent than azithromycin) (31).
The fluoro group incorporated into its structure imparts activity
against even highly resistant strains of multiple classes of micro-
organisms (38). It is acid stable with excellent oral bioavailability
and demonstrates excellent tissue uptake and accumulation (39);
it is also bactericidal at concentrations 2 to 8 times its MIC90 for
some pathogens (40). Solithromycin has a plasma half-life (t1/2) in
humans of approximately 7 h and has two polar phase I metabo-
lites, both of which are bioactive, although there are significant
species differences in the extent of metabolism (41, 42). Currently
in clinical trials (43), solithromycin appears to be well tolerated
and free of the adverse effects associated with its ketolide prede-
cessor telithromycin (43, 44).
Due to its excellent spectrum of activity against a wide range of
susceptible and resistant microorganisms, we believe solithromy-
cin may represent a significant therapeutic advance for the treat-
ment and prevention of intrauterine infections, depending on its
ability to cross the placenta and fetal membranes and reach the
fetus and amniotic cavity. The aim of the present study, therefore,
was to determine the pharmacokinetics and maternal-to-fetal
plasma transfer of solithromycin in a pregnant ovine model to
assess its potential for treating intrauterine and antenatal infec-
tion. An intravenous (i.v.) route of administration was selected to
avoid species differences in gastrointestinal uptake and metabo-
lism associated with oral administration. We also assessed amni-
otic-to-fetal transfer following i.a. administration for comparison
with our previous studies of azithromycin and erythromycin bio-
distribution using the same model (26).
MATERIALS AND METHODS
Surgical procedures and antibiotic administration. All experimental
procedures described in this study were approved by the Animal Ethics
Committee of The University of Western Australia. Details of animal
management, anesthesia, surgical catheterization, and recovery have been
described previously (26). Five days after surgery, at 116 1 days gesta-
tion, chronically catheterized pregnant ewes (65 kg) were randomly
selected to receive either (i) a single maternal i.v. infusion of 650 mg
solithromycin (10mg/kgmaternal weight; n 6 ewes) over 60min in 325
ml infusion buffer (5.77 g/liter tartaric acid, 50 g/liter mannitol, 5 g/liter
thioglycerol, buffered to pH 4.2 with NaOH), (ii) a single i.a. injection of
3.5 mg solithromycin (1.4 mg/kg fetal weight) in 3 ml perfusion buffer
(n  6 ewes), or (iii) a combination of maternal i.v. infusion and i.a.
injection (n 7 ewes). At this gestational age, fetal weight was estimated
to be 2.5 kg, and amniotic fluid volume was approximately 250 ml. Ma-
ternal and fetal arterial blood and amniotic fluid (two sets of 1ml) samples
were collected into heparinized tubes 30 min before and immediately
prior to the administration of the macrolide antibiotics as described
above; after the completion of antibiotic administration, samples were
taken at 0.5, 1, 2, 4, 8, 12, 24, 48, and 72 h. Fetal arterial PO2 (PaO2), PCO2
(PaCO2), O2 saturation (SaO2), pH (pHa), and electrolytes were mea-
sured with a Rapid Lab 1265 blood gas analyzer (Siemens, Germany).
Fetal and maternal plasma and amniotic fluid samples were stored at
80°C until they were shipped frozen to MicroConstants, Inc. (San Di-
ego, CA), for analysis of solithromycin and its metabolites.
Solithromycin concentration determination. Concentrations of so-
lithromycin and its two side-chain metabolites (CEM-214 and N-acetyl
[NAc]–CEM-101) in ovine plasma (maternal and fetal) and amniotic
fluid were assayed using high-performance liquid chromatography(H-
PLC)-tandem quadrupole mass spectrometry (MicroConstants’ analyti-
cal method MN12084). K3EDTA (anticoagulant) and internal standards
were added to the plasma and amniotic fluid samples, which were then
diluted with water, extracted using solid-phase extraction well plates, and
analyzed by reverse-phase HPLC using a Phenomenex Luna CN 100-Å
column maintained at 25°C. The mobile phase was 35% solvent A (20.0
mM ammonium formate, 0.2% formic acid, 0.0002% citric acid in water)
and 65% solvent B (0.1% formic acid in methanol-acetonitrile [50:50,
vol/vol]) at a flow rate of 0.3 ml/min. The retention times of CEM-101,
NAc–CEM-101, and CEM-214 were 2.1, 2.0, and 1.95 min, respectively.
The mobile phase was nebulized using heated nitrogen in a Z spray
source/interface set to electrospray positive ionization mode; the ionized
compounds were detected using tandem MS (MS/MS). The calibration
range of the assaywas from10 to 20,000 ng/ml for solithromycin and from
1 to 2,000 ng/ml for both CEM-214 and NAc–CEM-101. CEM-101–d3
(BioLink Life Sciences, Inc.) and NAc–CEM-101–d6 (Microconstants
Inc.) were used as the internal standards. The peak heights of solithromy-
cin, CEM-214, NAc–CEM-101, and the internal standards and subse-
quent calibration curves were acquired using MassLynx version 4.1 (Wa-
ters,Milford,MA). All samples were analyzed in a total of nine assay runs.
The coefficient of variation (CV) of themean plasma quality control (QC)
values (low, medium, and high) for solithromycin, CEM-214, and NAc–
CEM-101 ranged from 3.86 to 4.93%, 9.92 to 23.4%, and 3.59 to 10.4%,
respectively; in AF, the CV of the QC values ranged from 4.54 to 6.91%,
5.43 to 10.1%, and 3.34 to 7.96%, respectively. Methodological accuracy
for all three analytes was 6.7 to 10.0%.
Keelan et al.
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Statistical and pharmacokinetic analysis. Antibiotic concentration
data from n 6 or 7 animals per time point were grouped, and the mean,
standard deviation, and standard error of themeanwere calculated. Phar-
macokinetic analysis was performed using PKSolver software (45). Ma-
ternal and fetal solithromycin pharmacokinetic data were fitted using a
two-compartment model, whereas the i.a. solithromycin administration
data and all metabolite data were best described by a noncompartmental
model.
RESULTS
Maternal i.v. administration. The pharmacokinetics of maternal
i.v. solithromycin displayed characteristics in the pregnant sheep
that are broadly similar to those reported in adult humans and
other animal models (Fig. 1A). Peak concentrations of 1,073
ng/ml were obtained 30 min after maternal i.v. infusion (t  1.5
h), which declined steadily with a half-life (t1/2) of 6 h, resulting in
an area under the concentration-time curve from 0 to infinity
(AUC0–) of greater than 6,500 ng/ml · h (Table 1). The acetylated
metabolite NAc–CEM-101 was present in low but readily detect-
able levels inmaternal plasma, reaching peak concentrations (69.2
ng/ml) at 4 h postinfusion that were approximately 7% of the
maximal parent drug concentrations (Fig. 1B). The maternal
plasma half-life of NAc–CEM-101 was similar to that of solithro-
mycin, although themean residence time (MRT) was slightly lon-
ger (8.5 h compared to 7.4 h) (Table 2). The bioactive metabolite
CEM-214, which is formed by loss of the aminophenyl-1,2,3-tri-
azole chain of solithromycin, was detected at levels higher than
those of NAc–CEM-101 (97.6 ng/ml at 1 h postinfusion, 10.7% of
the solithromycin concentration) and remained detectable for at
least 24 h (Fig. 1C) with a t1/2 of 7.9 h (Table 3). At t  2 h, the
combined level of side-chain metabolites was 18% of the parent
drug, somewhat higher than that reported for humans (approxi-
mately 8% after i.v. administration) (41).
Solithromycin concentrations in fetal plasma peaked 1 to 2
h postinfusion, reaching concentrations of 350 ng/ml (Fig.
1A), representing a placental transfer efficiency of 34%.
Clearance from the fetal compartment was similar to that in the
maternal circulation, with a t1/2 of 6.2 h; fetal circulating con-
centrations were stable for the first 2 h after infusion and re-
mained at therapeutic levels for over 12 h following a single
maternal dose. The AUC0– in the fetal compartment was
2,971 ng/ml · h (Table 1). In the fetal compartment, NAc–
CEM-101 levels reached almost half those of CEM-101 at 2 h
postinfusion (148 ng/ml); however, it was cleared more slowly,
with a half-life of 7.6 h and an MRT of 9.7 h (Table 2) (Fig. 1B).
FIG 1 Concentrations of solithromycin (CEM-101) (A),N-acetyl solithromycin (NAc–CEM-101) (B), and CEM-214 (C) inmaternal plasma, fetal plasma, and
amniotic fluid after a single maternal dose of solithromycin (650 mg, 10 mg/kg maternal weight) by i.v. infusion. Data are shown as means standard errors of
the means (SEM) (n 6 or 7 animals).
TABLE 1 Pharmacokinetic parameters of solithromycin in maternal,
fetal, and amniotic compartments after administration of solithromycin
via maternal i.v. infusion or i.a. injectiona
Parameter
Value
Maternal i.v. i.a. injection
MP FP AF MP FP AF
Cmax (ng/ml) 1,073.1 353.4 214.4 11.3 81.0 52,700
Tmax (h) 1.5 2 5 5 4 1.5
t1/2 (h) 6.0 6.2 21.5 NC 7.0 16.8
AUC0– (ng/ml · h) 6,545 2,971 6,458 NC 981.5 317,808
MRT0– (h) 7.4 8.5 30.6 NC 10.1 11.2
CL (mg/ng/ml/h) 0.099 0.22 0.101 NC 0.004 0.001
Vss (mg/ng/ml) 0.633 1.64 2.981 NC 0.033 0.001
a MP, maternal plasma; FP, fetal plasma; AF, amniotic fluid. The start of infusion was
designated as t 0. AUC0–, area under the curve from 0 to infinity; MRT, mean
residence time; CL, clearance; Vss, volume of distribution at steady state; Tmax, time to
maximum concentration of drug in serum; NC, not calculated due to insufficient data;
Cmax, maximum concentration of drug in serum.
TABLE 2 Pharmacokinetic parameters of N-acetyl–CEM-101 in
maternal, fetal, and amniotic compartments after administration of
solithromycin via maternal i.v. infusion or i.a. injectiona
Parameter
Value
Maternal i.v. i.a. injection
MP FP AF MP FP AF
Cmax (ng/ml) 69.12 148.3 96.2 2.7 33.2 512.2
Tmax (h) 5 3 13 9 5 9
t1/2 (h) 6.0 7.6 33.8 12.2 6.7 21.8
AUC0– (ng/ml · h) 789.5 1,635.7 4,226.5 64.2 490.8 18,414
MRT0– (h) 8.5 9.7 49.2 19.1 11.5 33.0
CL (mg/ng/ml/h) 0.823 0.397 0.154 0.055 0.007 0.0002
Vss (mg/ng/ml) 6.16 3.47 7.41 0.99 0.075 0.0061
a The start of infusion was designated as t 0. MP, maternal plasma; FP, fetal plasma;
AF, amniotic fluid; AUC0–, area under the curve from 0 to infinity; MRT, mean
residence time; CL, clearance; Vss, volume of distribution at steady state; Tmax, time to
maximum concentration of drug in serum; Cmax, maximum concentration of drug in
serum.
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Levels of CEM-214 were lower than NAc–CEM-101 (35 ng/ml
at 2 h postinfusion) but exhibited a similar pharmacokinetic
profile (Table 3).
Amniotic fluid concentrations of solithromycin had the lowest
maximum concentration of drug in serum (Cmax) of the three
compartments, 214 ng/ml at 4 to 8 h aftermaternal infusion; how-
ever, due to its very slow clearance and long half-life (21.5 h),
therapeutic levels were sustained at30 ng/ml for over 48 h (Fig.
1A). Accordingly, the AUC0– in amniotic fluid was high: 6,458
ng/ml · h (Table 1). Concentrations of NAc–CEM-101 in AF rose
steadily during the first 12 h postinfusion, reaching a Cmax of 96
ng/ml at 12 h, before declining slowly to 20 ng/ml at 72 h (Fig. 1B).
This resulted in a longMRT (49 h) and a highAUC (4,226 ng/ml · h)
(Table 2). CEM-214 also slowly accumulated inAF during the first
12 h postinfusion (Fig. 1C), exhibiting a t1/2 of 31.6 h and aCmax at
13 h of 44.2 ng/ml (Table 3). Bothmetabolites were still detectable
in AF at the 72-h time point.
Intra-amniotic administration. Administration of solithro-
mycin (3.5 mg) into the amniotic cavity resulted in peak AF con-
centrations ranging from 18.9 to 92.8 	g/ml (mean, 52.7 	g/ml)
(Fig. 2A). Concentrations declined slowly but steadily, with a t1/2
of 16 h; the AUC0– was extremely high at 317,000 ng/ml · h,
and concentrations remained well above therapeutic levels (100
ng/ml) throughout the 72-h experimental period (Fig. 2A). Trans-
fer from the amniotic to fetal compartment was poor, however,
with fetal plasma levels peaking at 1.5% of maximal amniotic
fluid levels (81 ng/ml at 2 h postinfusion). Nevertheless, fetal
plasma solithromycin levels were sustained above 30 ng/ml for 24
h (t1/2 of 7 h; MRT of10 h) (Fig. 2A). Maternal concentrations
barely exceeded the limit of quantitation (10 ng/ml) and only at
the 4- to 12-h time points, indicating a very low efficiency of AF-
to-maternal plasma transfer (0.05%).
NAc–CEM-101 was readily detectable after i.a. solithromycin
administration in all three compartments, peaking at 8 h in
amniotic fluid at levels nearly 5%of those of the parent drug at the
same time point (512 ng/ml) (Fig. 2B). TheMRT in amniotic fluid
(33 h) was considerably longer than that for the parent drug (11
h). Fetal concentrations were lower (Cmax of 33 ng/ml at 4 h
postinfusion) but showed a similar profile, falling after t  9 h
postinfusion and remaining detectable until after 24 h. Maternal
levels also peaked at 9 h but never exceeded 3 ng/ml. The levels of
CEM-214 in all three compartments following i.a. solithromycin
administration were on the borderline of detectability and data
could not be analyzed.
Combinedmaternal and intra-amniotic administration.The
combination of maternal i.v. and i.a. administration resulted in
peak fetal concentrations about 25%higher than levels that would
be predicted on a simple additive basis (Fig. 3A). At 1 h postinjec-
tion/postinfusion, fetal plasma levels reached 511 ng/ml and then
declinedwith a t1/2 of 5.2 h; the AUC0–was 4,880 ng/ml · h (Table
1). In the amniotic cavity, the combination of i.v. plus i.a. admin-
istration did not initially alter CEM-101 concentrations above the
expected levels, but between 12 to 28 h the levels were sustained at
2-fold-higher concentrations than the simple combination
would have predicted (Fig. 3A). Maternal concentrations were
similar to those expected.
Levels of NAc–CEM-101 in all three compartments were
within the range expected based on a simple combination of the
i.v. and i.a. doses (Fig. 3B). However, CEM-214 concentrations in
TABLE 3 Pharmacokinetic parameters of CEM-214 in maternal, fetal,
and amniotic compartments after administration of solithromycin via
maternal i.v. infusion or a combination of i.v. infusion and i.a.
injectiona
Parameter
Value
Maternal i.v. Combined i.v. and i.a.
MP FP AF MP FP AF
Cmax (ng/ml) 9.6 57.3 44.2 125.8 48.3 198.2
Tmax (h) 2 5 13 2 9 25
t1/2 (h) 7.9 6.9 31.6 12.4 8.1 14.9
AUC0– (ng/ml · h) 1,292 538 1,582 2,800 868 7,782
MRT0– (h) 10.4 9.4 42.3 15.9 12.9 29.9
CL (mg/ng/ml/h) 0.503 1.21 0.411 0.232 0.748 0.084
Vss (mg/ng/ml) 4.74 10.2 16.95 3.46 8.93 2.41
a Concentrations of CEM-214 with i.a. injection alone were low or nondetectable in all
compartments and insufficient for pharmacokinetic calculations. The start of infusion
was designated as t 0. MP, maternal plasma; FP, fetal plasma; AF, amniotic fluid;
AUC0–, area under the curve from 0 to infinity; MRT, mean residence time; CL,
clearance; Vss, volume of distribution at steady state; Tmax, time to maximum
concentration of drug in serum; Cmax, maximum concentration of drug in serum.
FIG 2 Concentrations of solithromycin (A) and its metabolite NAc–CEM-101 (B) in maternal plasma, fetal plasma, and amniotic fluid after a single amniotic
dose (3.5 mg, 1.4 mg/kg fetal weight) by intra-amniotic (i.a.) injection. Data are shown as means  SEM (n  6 or 7 animals). Note log concentration axes.
CEM-214 concentrations were at or below the limit of detection (data not shown).
Keelan et al.
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AF showed an interesting and unexpected response to the combi-
nation dose (Fig. 3C and Table 3). With combined i.v. and i.a.
CEM-101 administration, AF levels of CEM-214 showed a
marked late-onset rise, reaching200 ng/ml at 8 to 24 h postin-
fusion. This is 4-fold higher than that observed in the i.v.-only
group, despite the fact that in the i.a. group, CEM-214 concentra-
tions in AF were undetectable. The AF AUC0– in the combined
i.v. and i.a. group wasmuch higher than in thematernal i.v. group
(7,782 compared to 1,582 ng/ml · h). PlasmaCEM-214 levels were
predictable and did not show this counterintuitive response to the
combined dose.
Comparison with azithromycin. Our previous studies of
macrolide biodistribution in pregnancy using the same model at
the same gestational age observed very low rates of transfer of
macrolides from the maternal compartment to the fetal or amni-
otic compartment (26). To highlight the differences between
solithromycin and azithromycin, maternal plasma, fetal plasma,
and AF concentrations of both antibiotics were plotted on the
same graph for 48 h aftermaternal i.v. infusion. As shown in Fig. 4,
the concentrations of solithromycin in the fetal and amniotic
compartments were dramatically higher than azithromycin, with
solithromycin achieving and sustaining therapeutic concentra-
tions for at least 12 h (48 h in the amniotic cavity). At the 4-h time
point, the maternal-to-fetal plasma and maternal-to-AF plasma
transfer rates of azithromycin were 1.4% and 13.3%, respectively,
whereas the equivalent figures for solithromycin were 51.6% and
47.9%.
DISCUSSION
The central finding of this study is that a single dose of solithro-
mycin given maternally can be an effective mode of delivery of
antibiotic to both the fetal and amniotic compartments. As-
suming this finding is replicated in human pregnancy, this is an
extremely significant observation clinically, as currently avail-
able macrolides have limited oral bioavailability and do not
transfer efficiently from the maternal compartment to the fetal
compartment (unless given over extended periods of time).
Consequently, maternal therapy provides poor antimicrobial
protection for the amniotic cavity (including the fetus). This is
likely to be a major factor contributing to the poor success rates
of macrolides in the prevention of preterm birth and reduction
of associated neonatal morbidity and mortality. The fact that
solithromycin is considerably more potent than existing mac-
rolides, has a high level of oral bioavailability, exhibits signifi-
cant cellular accumulation, and, most importantly, is very ef-
fective against most macrolide-resistant strains of target
organisms (31) makes maternal solithromycin administration
an extremely attractive therapeutic prospect for treating and
preventing intrauterine infections in pregnancy.
In adult humans, solithromycin pharmacokinetic parameters
FIG 3 Concentrations of solithromycin (CEM-101) (A), NAc–CEM-101 (B), and CEM-214 (C) in maternal plasma, fetal plasma, and amniotic fluid after
combined maternal (10 mg/kg) and intra-amniotic (1.4 mg/kg) administration of solithromycin. Data are shown as means SEM (n 6 or 7 animals). Note
the log concentration axis in panel A.
FIG 4 Comparison of solithromycin and azithromycin pharmacokinetic profiles in maternal plasma (A), fetal plasma (B), and amniotic fluid (C) after a single
maternal dose by i.v. infusion (10 mg/kg solithromycin, 5 mg/kg azithromycin; single dose).
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(Cmax, t1/2, and AUC0–) following a 600-mg oral dose are 862
ng/ml, 5.5 h, and 9,049 ng/ml · h, respectively (42). These data are
reasonably similar to the present figures inmaternal sheep plasma
at a similar dose (1,073 ng/ml, 6.0 h, 6,545 ng/ml · h, respectively),
suggesting that the pharmacokinetics are broadly similar in both
species. While the ovine placenta differs structurally and anatom-
ically from the human placenta in a number of important ways
(46), the pregnant ewe remains a useful model to study placental
transport and fetal growth and development (47). In our earlier
studies in the same model, azithromycin (at half the dose) was
cleared from maternal plasma considerably more rapidly than
solithromycin (t1/2 of 1.3 h), although the AUC0– was similar
(6,227 ng/ml · h) (26). Surprisingly, in light of the immaturity of
the fetus in terms of drugmetabolic and secretory capacity, the t1/2
and MRT of solithromycin in fetal plasma appear to be only
slightly longer than in the maternal circulation. This may relate to
the mode of excretion of solithromycin. In adults, there is some
evidence to suggest that solithromycin and an N-demethylated
metabolite are eliminated in the bile (Cempra Inc., unpublished
findings). Both human and ovine fetuses are known to have an
immature but partially functional biliary secretion system (48,
49), presumably capable of eliminating small amounts of solithro-
mycin. Repeated doses, therefore, may be expected to result in
delayed elimination and associated changes in pharmacokinetic
parameters. Future studies will need to explore this to ensure that
fetal concentrations do not increase to toxic levels following mul-
tiple doses.
Fetal plasma solithromycin concentrations reached peak levels
(350 to 400 ng/ml) 1 h after maternal infusion, suggesting a
relatively high rate of transplacental passage. The efficiency of
transfer (30 to 50%) was much greater than existing macrolides,
which are1% in the sameovinemodel (26) and4% inhumans
(25). The relatively static levels of solithromycin found in the
amniotic fluid probably reflects the initial accumulation of the
antibiotic from fetal excretion and transplacental and transcho-
rioamnion diffusion, in conjunction with a low rate of clearance
(t1/2 of 20 h, similar to the t1/2 of azithromycin in AF of 17.5 h
[26]). Hence, despite the Cmax in AF barely exceeding 200 ng/ml,
the AUC was equivalent to that in MP (6,000 ng/ml · h) and
more than twice that in FP (2,971 ng/ml · h). Collectively, these
data suggest that a single maternal 650-mg solithromycin dose is
sufficient to give adequate therapeutic antibiotic levels in the fetal
and amniotic compartments.
The MIC90 for solithromycin against most macrolide-suscep-
tible strains of Ureaplasma spp., Mycoplasma spp., streptococci,
and staphylococci is30 ng/ml (31, 34, 38). Farrell and colleagues
tested solithromycin in vitro against a large number (10,000) of
clinical bacterial pathogens and reported that the largemajority of
isolates of Streptococcus pneumoniae, Staphylococcus aureus, coag-
ulase-negative staphylococci, beta-hemolytic streptococci, viri-
dans group streptococci, andMoraxella catarrhaliswere inhibited
by 60 ng/ml solithromycin (34). Based on this cutoff, a single
maternal dose would be expected to provide antimicrobial cover-
age in maternal plasma, fetal plasma, and AF for 12, 12, and
24 h, respectively. More resistant strains of these organisms and
of other less susceptible species, such as Haemophilus influenzae
and enterococci, required higher concentrations (500 to 2,000 ng/
ml) to achieve effective inhibition (34). Repeated maternal ad-
ministration is likely to be needed to achieve these concentrations
in the amniotic cavity. Alternatively, as we have shown in this
study, a single intra-amniotic dose would be sufficient in theory to
eliminate even highly resistantmicroorganisms from the amniotic
cavity. A combined i.v.-i.a. regimen might, therefore, have signif-
icant therapeutic advantages in terms of eradication of resistant or
persistent intra-amniotic infections unresponsive to maternal ad-
ministration alone.
Detailed studies of solithromycin metabolism and the bioac-
tivity of its metabolites have not yet been carried out. In prelimi-
nary studies, the two known urinary excretion products of soli-
thromycinmetabolism, NAc–CEM-101 and CEM-214, have been
found to possess approximately 50%and 25%of the activity of the
parent compound against susceptible strains of Gram-positive or-
ganisms, although against resistant organisms they are markedly
less effective (41). Their relative efficacy against Ureaplasma and
Mycoplasma spp. is currently being evaluated, although these
studies are not yet complete; therefore, definitive assessment of
their bioactivity is currently lacking. These metabolites were both
present in the maternal circulation at low but readily detectable
levels, 5 to 10% of the concentrations of the parent drug. In this
regard, the sheep and mouse are similar. Humans, on the other
hand, produce less of both metabolites, while monkeys produce
10-foldmore and rats producemoreNAc–CEM-101 but almost
noCEM-214 after oral administration (41). The delayed clearance
of the metabolites in AF results in extended duration of their ef-
fects (i.e., high AUC) in this compartment. Taking into account
the preliminary data available on the relative potency of CEM-101
and its metabolites (approximately 1:0.5:0.25) and applying this
to the individual AUCvalues forCEM-101 and itsmetabolites, the
net combined AUCs in maternal plasma, fetal plasma, and AF
following thematernal i.v. dose are 7,263, 3,923, and 8,967 ng/ml · h,
respectively.Hence, themetabolites are likely to play a particularly
significant contribution to solithromycin’s antimicrobial effects
in the amniotic cavity.
Solithromycin’s spectrum of activity is particularly perti-
nent to the treatment of bacterial genital tract infections. Not
only is it extremely effective against Mollicutes (Ureaplasma and
Mycoplasma spp.), the organisms most commonly isolated from
amniotic fluid following preterm labor or PPROM, but it is also
highly effective against other important genital tract pathogens,
such as group B streptococci, N. gonorrhoeae, and C. trachomatis
(32, 34–40). Assuming that the present findings can be replicated
in human pregnancy, then administration of solithromycin to
women in preterm labor or PPROMwould be expected to consti-
tute a markedly more effective antenatal antimicrobial therapy
than currently used macrolides, with commensurate benefits in
the reduction of neonatal infections and associatedmorbidity and
mortality. For asymptomatic women early in pregnancy at risk of
infection-driven preterm birth, maternal solithromycin adminis-
trationmay offer an effective therapeutic approach for the preven-
tion of preterm birth. Studies are under way to assess the transfer
and metabolism of solithromycin by the human placenta.
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